These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

205 related articles for article (PubMed ID: 31831875)

  • 1. Next-generation hypomethylating agent SGI-110 primes acute myeloid leukemia cells to IAP antagonist by activating extrinsic and intrinsic apoptosis pathways.
    Dittmann J; Haydn T; Metzger P; Ward GA; Boerries M; Vogler M; Fulda S
    Cell Death Differ; 2020 Jun; 27(6):1878-1895. PubMed ID: 31831875
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dual Antagonist of cIAP/XIAP ASTX660 Sensitizes HPV
    Xiao R; An Y; Ye W; Derakhshan A; Cheng H; Yang X; Allen C; Chen Z; Schmitt NC; Van Waes C
    Clin Cancer Res; 2019 Nov; 25(21):6463-6474. PubMed ID: 31266830
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The non-peptidomimetic IAP antagonist ASTX660 sensitizes colorectal cancer cells for extrinsic apoptosis.
    Knoll G; Ehrenschwender M
    FEBS Open Bio; 2021 Mar; 11(3):714-723. PubMed ID: 33484626
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical Positioning of the IAP Antagonist Tolinapant (ASTX660) in Colorectal Cancer.
    Crawford N; Stott KJ; Sessler T; McCann C; McDaid W; Lees A; Latimer C; Fox JP; Munck JM; Smyth T; Shah A; Martins V; Lawler M; Dunne PD; Kerr EM; McDade SS; Coyle VM; Longley DB
    Mol Cancer Ther; 2021 Sep; 20(9):1627-1639. PubMed ID: 34389694
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Smac mimetic primes apoptosis-resistant acute myeloid leukaemia cells for cytarabine-induced cell death by triggering necroptosis.
    Chromik J; Safferthal C; Serve H; Fulda S
    Cancer Lett; 2014 Mar; 344(1):101-109. PubMed ID: 24184825
    [TBL] [Abstract][Full Text] [Related]  

  • 6. ASTX660, an antagonist of cIAP1/2 and XIAP, increases antigen processing machinery and can enhance radiation-induced immunogenic cell death in preclinical models of head and neck cancer.
    Ye W; Gunti S; Allen CT; Hong Y; Clavijo PE; Van Waes C; Schmitt NC
    Oncoimmunology; 2020; 9(1):1710398. PubMed ID: 32002309
    [TBL] [Abstract][Full Text] [Related]  

  • 7. ASTX660, a Novel Non-peptidomimetic Antagonist of cIAP1/2 and XIAP, Potently Induces TNFα-Dependent Apoptosis in Cancer Cell Lines and Inhibits Tumor Growth.
    Ward GA; Lewis EJ; Ahn JS; Johnson CN; Lyons JF; Martins V; Munck JM; Rich SJ; Smyth T; Thompson NT; Williams PA; Wilsher NE; Wallis NG; Chessari G
    Mol Cancer Ther; 2018 Jul; 17(7):1381-1391. PubMed ID: 29695633
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Smac mimetic and demethylating agents synergistically trigger cell death in acute myeloid leukemia cells and overcome apoptosis resistance by inducing necroptosis.
    Steinhart L; Belz K; Fulda S
    Cell Death Dis; 2013 Sep; 4(9):e802. PubMed ID: 24030154
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Synergistic targeting of AML stem/progenitor cells with IAP antagonist birinapant and demethylating agents.
    Carter BZ; Mak PY; Mak DH; Shi Y; Qiu Y; Bogenberger JM; Mu H; Tibes R; Yao H; Coombes KR; Jacamo RO; McQueen T; Kornblau SM; Andreeff M
    J Natl Cancer Inst; 2014 Feb; 106(2):djt440. PubMed ID: 24526787
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Therapeutic targeting of necroptosis by Smac mimetic bypasses apoptosis resistance in acute myeloid leukemia cells.
    Safferthal C; Rohde K; Fulda S
    Oncogene; 2017 Mar; 36(11):1487-1502. PubMed ID: 27869161
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Identification of a novel synergistic induction of cell death by Smac mimetic and HDAC inhibitors in acute myeloid leukemia cells.
    Steinwascher S; Nugues AL; Schoeneberger H; Fulda S
    Cancer Lett; 2015 Sep; 366(1):32-43. PubMed ID: 26028172
    [TBL] [Abstract][Full Text] [Related]  

  • 12. RIP1 is required for IAP inhibitor-mediated sensitization for TRAIL-induced apoptosis via a RIP1/FADD/caspase-8 cell death complex.
    Abhari BA; Cristofanon S; Kappler R; von Schweinitz D; Humphreys R; Fulda S
    Oncogene; 2013 Jul; 32(27):3263-73. PubMed ID: 22890322
    [TBL] [Abstract][Full Text] [Related]  

  • 13. X-linked inhibitor of apoptosis inhibition sensitizes acute myeloid leukemia cell response to TRAIL and chemotherapy through potentiated induction of proapoptotic machinery.
    Zhou J; Lu X; Tan TZ; Chng WJ
    Mol Oncol; 2018 Jan; 12(1):33-47. PubMed ID: 29063676
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Medicarpin, a legume phytoalexin sensitizes myeloid leukemia cells to TRAIL-induced apoptosis through the induction of DR5 and activation of the ROS-JNK-CHOP pathway.
    Trivedi R; Maurya R; Mishra DP
    Cell Death Dis; 2014 Oct; 5(10):e1465. PubMed ID: 25321472
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Synergistic interaction of Smac mimetic and IFNα to trigger apoptosis in acute myeloid leukemia cells.
    Bake V; Roesler S; Eckhardt I; Belz K; Fulda S
    Cancer Lett; 2014 Dec; 355(2):224-31. PubMed ID: 25179908
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Triptolide sensitizes AML cells to TRAIL-induced apoptosis via decrease of XIAP and p53-mediated increase of DR5.
    Carter BZ; Mak DH; Schober WD; Dietrich MF; Pinilla C; Vassilev LT; Reed JC; Andreeff M
    Blood; 2008 Apr; 111(7):3742-50. PubMed ID: 18187663
    [TBL] [Abstract][Full Text] [Related]  

  • 17. TAS4464, a NEDD8-activating enzyme inhibitor, activates both intrinsic and extrinsic apoptotic pathways via c-Myc-mediated regulation in acute myeloid leukemia.
    Ochiiwa H; Ailiken G; Yokoyama M; Yamagata K; Nagano H; Yoshimura C; Muraoka H; Ishida K; Haruma T; Nakayama A; Hashimoto N; Murata K; Nishimura M; Kawashima Y; Ohara O; Ohkubo S; Tanaka T
    Oncogene; 2021 Feb; 40(7):1217-1230. PubMed ID: 33420360
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Survivin inhibitor YM-155 sensitizes tumor necrosis factor- related apoptosis-inducing ligand-resistant glioma cells to apoptosis through Mcl-1 downregulation and by engaging the mitochondrial death pathway.
    Premkumar DR; Jane EP; Foster KA; Pollack IF
    J Pharmacol Exp Ther; 2013 Aug; 346(2):201-10. PubMed ID: 23740602
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Guadecitabine (SGI-110): an investigational drug for the treatment of myelodysplastic syndrome and acute myeloid leukemia.
    Daher-Reyes GS; Merchan BM; Yee KWL
    Expert Opin Investig Drugs; 2019 Oct; 28(10):835-849. PubMed ID: 31510809
    [No Abstract]   [Full Text] [Related]  

  • 20. Cotreatment with Smac mimetics and demethylating agents induces both apoptotic and necroptotic cell death pathways in acute lymphoblastic leukemia cells.
    Gerges S; Rohde K; Fulda S
    Cancer Lett; 2016 May; 375(1):127-132. PubMed ID: 26944210
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.